Retrospective study of 1st SLE pregnancies from LUNA Registry. Fetal loss was associated w/ aPL (OR 2.46) & pulse steroids (2.46), but not w/ SSA Abs (1.32). 247 pregs, 194 live births, 53 fetal loss. Ro+ vs Ro- no difference in live births or preterm births https://t.co/bsMMvVyffw

What's it like to have #RA? RICHARD: "There were days that I couldn’t mask the pain or hide the limp..So I tried to deny and hide the disease. I would always go up and down stairs when no one was looking. I got up extra early so no one could see me walk like an old man to the https://t.co/krHn4yoRYd

5 Retrospective cohorts of PM/DM pts showed IIM (myositis) had signif higher risks of IIM patients HTN w/ pregnancy (OR 2.73), & C-section (OR 2.03). Also more preterm birth (3.7), SGA/IUGR (1.9) https://t.co/w6qymR0I2w https://t.co/ovtwdleRfE

A new review of the GLP-1 receptor drugs @NEJM https://t.co/PK03jApZWB surprisingly, the word inflammation only appears once, in this diagram https://t.co/1PeBakBAQb

Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UbEoBz37hT https://t.co/V9WzfRtbFQ

Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis The TOGETHER-PsA trial has demonstrated the efficacy and safety of ixekizumab (IXE) administered with tirzepatide (TZP) in adult active psoriatic arthritis (PsA) patients who were overweight or obese. https://t.co/KFwfi9FaAh

What's it like to have #RA? PATTY "To find patients or doctors who can talk intelligently about RA is a welcomed relief. However, I prefer that those around me not know about me and my RA. I hope they don’t notice the changes in my hands or shoes or that I cannot wear my usual https://t.co/OQbXJrcyPp

After hours EHR catchup has been coined "Pajama time" by residents & physicians & contributes to burnout. Survey 9,731 YR 2 Family Med residents- spend 3+ hrs/d after wk on ambulatory EHRs. Pajama time assoc w/ less knowledge, professional satisfaction, more burnout. https://t.co/QSR7VM2T7u

Brepocitinib in Dermatomyositis The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose. https://t.co/YNxrVTIubb https://t.co/uFY3kMOvui

AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB

FDA has issued a drug safety warning for avacopan (Tavneos), dentifying 76 cases of drug-induced liver injury, including 7 cases of rare vanishing bile duct syndrome (VBDS). There were 8 deaths https://t.co/WkBhs1rNpf https://t.co/ZXdHsAJUOQ